Literature DB >> 34601644

Interactive effect of sarcopenia and falls on vertebral osteoporotic fracture in patients with rheumatoid arthritis.

Jing-Jing Tong1, Sheng-Qian Xu2, Jian-Xiong Wang1, He-Xiang Zong1, Yi-Ran Chu1, Ke-Ming Chen1, Yu-Zhu Teng1.   

Abstract

Patients with rheumatoid arthritis (RA) had higher incidences of sarcopenia, falls, osteoporosis, and vertebral osteoporotic fractures (VOPF). Sarcopenia was associated with longer disease duration, higher disease activity, and more severe RA. The interactive effect of sarcopenia and falls was associated with a higher risk of VOPF in patients with RA.
PURPOSE: Whether sarcopenia and falls are a risk factor for vertebral fracture in RA patients has not been demonstrated. This study aimed to explore the incidence of vertebral osteoporotic fracture (VOPF) and its relationship with sarcopenia and falls in RA patients.
METHODS: A total of 474 RA patients and 156 controls were enrolled in this study. Anteroposterior and lateral X-ray examinations of the vertebral column (T4-L4) were used for the semiquantitative assessment of VOPF. Bone mineral density was measured by dual-energy X-ray absorptiometry. Skeletal muscle mass was measured by direct segmental multifrequency bioelectrical impedance analysis (DSM-BIA method).
RESULTS: RA patients had an increased risk of sarcopenia (62.4% vs 9.0%, x2 = 47.478, P < 0.001), falls (30.2% vs 3.2%), osteoporosis (OP) (33.5% vs 12.8%, x2 = 134.276, P < 0.001), and VOPF (20.3% vs 3.8%, x2 = 47.478, P < 0.001) than controls. Patients with sarcopenia were more likely to have VOPF than RA without sarcopenia (24.0% vs 14.0%, x2 = 6.802, P = 0.009). RA with sarcopenia and prior falls had the highest incidences of VOPF (36.7%). Older age (OR = 1.056, P < 0.001, 95% CI 1.030-1.083), falls (OR = 2.043, P = 0.003, 95% CI 1.238-3.371), OP (OR = 1.819, P = 0.034, 95% CI 1.046-3.163), and usage of glucocorticoids (GCs) (OR = 1.862, P = 0.022, 95% CI 1.093-3.172) were risk factors for VOPF in RA patients, while a higher skeletal muscle index (SMI) was a protective factor (OR = 0.754, P = 0.038, 95% CI 0.578-0.984) for VOPF in RA patients.
CONCLUSIONS: The interactive effect of sarcopenia and falls is associated with a higher risk of VOPF in patients with RA.
© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.

Entities:  

Keywords:  Rheumatoid arthritis; Sarcopenia; Vertebral osteoporotic fracture

Mesh:

Year:  2021        PMID: 34601644     DOI: 10.1007/s11657-021-01017-1

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  32 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Fall incidence and fall risk factors in people with rheumatoid arthritis.

Authors:  E Smulders; C Schreven; V Weerdesteyn; F H J van den Hoogen; R Laan; W Van Lankveld
Journal:  Ann Rheum Dis       Date:  2009-11       Impact factor: 19.103

3.  Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis.

Authors:  Mie Torii; Motomu Hashimoto; Akiko Hanai; Takao Fujii; Moritoshi Furu; Hiromu Ito; Ryuji Uozumi; Masahide Hamaguchi; Chikashi Terao; Wataru Yamamoto; Miyabi Uda; Kazuko Nin; Satoshi Morita; Hidenori Arai; Tsuneyo Mimori
Journal:  Mod Rheumatol       Date:  2018-09-11       Impact factor: 3.023

Review 4.  Sarcopenia: origins and clinical relevance.

Authors:  I H Rosenberg
Journal:  J Nutr       Date:  1997-05       Impact factor: 4.798

5.  Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture.

Authors:  Marco Di Monaco; Fulvia Vallero; Roberto Di Monaco; Rosa Tappero
Journal:  Arch Gerontol Geriatr       Date:  2010-03-05       Impact factor: 3.250

6.  Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.

Authors:  Liang-Kung Chen; Li-Kuo Liu; Jean Woo; Prasert Assantachai; Tung-Wai Auyeung; Kamaruzzaman Shahrul Bahyah; Ming-Yueh Chou; Liang-Yu Chen; Pi-Shan Hsu; Orapitchaya Krairit; Jenny S W Lee; Wei-Ju Lee; Yunhwan Lee; Chih-Kuang Liang; Panita Limpawattana; Chu-Sheng Lin; Li-Ning Peng; Shosuke Satake; Takao Suzuki; Chang Won Won; Chih-Hsing Wu; Si-Nan Wu; Teimei Zhang; Ping Zeng; Masahiro Akishita; Hidenori Arai
Journal:  J Am Med Dir Assoc       Date:  2014-02       Impact factor: 4.669

7.  Diagnostic criteria for primary osteoporosis: year 2012 revision.

Authors:  Satoshi Soen; Masao Fukunaga; Toshitsugu Sugimoto; Teruki Sone; Saeko Fujiwara; Naoto Endo; Itsuo Gorai; Masataka Shiraki; Hiroshi Hagino; Takayuki Hosoi; Hiroaki Ohta; Toshiyuki Yoneda; Tatsushi Tomomitsu
Journal:  J Bone Miner Metab       Date:  2013-04-04       Impact factor: 2.626

8.  A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis.

Authors:  H W Minne; G Leidig; C Wüster; L Siromachkostov; G Baldauf; R Bickel; P Sauer; M Lojen; R Ziegler
Journal:  Bone Miner       Date:  1988-03

9.  Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis.

Authors:  Jing-Jing Tong; Sheng-Qian Xu; He-Xiang Zong; Mei-Juan Pan; Yu-Zhu Teng; Jian-Hua Xu
Journal:  Clin Rheumatol       Date:  2019-11-05       Impact factor: 2.980

10.  Prevalence of Sarcopenia and Its Relationship with Sites of Fragility Fractures in Elderly Chinese Men and Women.

Authors:  Wei Hong; Qun Cheng; Xiaoying Zhu; Hanmin Zhu; Huilin Li; Xuemei Zhang; Songbai Zheng; Yanping Du; Wenjing Tang; Sihong Xue; Zhibin Ye
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more
  1 in total

Review 1.  The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.

Authors:  Thales R Hein; Leonardo Peterson; Barbara J Bartikoski; Juliana Portes; Rafaela C Espírito Santo; Ricardo M Xavier
Journal:  Arthritis Res Ther       Date:  2022-07-19       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.